Oppenheimer is making some adjustments to its estimates on BioSante Pharmaceuticals, Inc. BPAX
“We note BPAX's cash balance of ~$51M, which we believe is sufficient to fund operations into 2012,” Oppenheimer writes. “We adjust our 2011 EPS estimate to ($0.69) from ($0.43) and our 2012 EPS estimate to ($0.33) from $0.29, which reflects our current estimate of a 2012 LibiGel launch.”
BioSante closed Tuesday at $2.35.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in